Comparative screening and validation as a novel tool to identify STAT-specific inhibitors

Area of Science:

• Molecular Biology
• Biochemistry
• Pharmacology

Background:

• Signal transducers and activators of transcription (STATs) are key in cellular signaling pathways, regulating gene transcription.
• Dysregulated STAT signaling is linked to various diseases, including cancer, inflammation, and autoimmune disorders.
• Current STAT inhibitor development faces challenges in specificity and efficacy, with no FDA-approved drugs yet.

Purpose of the Study:

• To develop a novel pipeline for identifying specific and potent inhibitors targeting human STAT (hSTAT) proteins.
• To address the limitations of existing screening strategies for STAT-targeting compounds.
• To provide tools for better understanding STAT functions in disease and developing new therapeutic strategies.

Main Methods:

• Utilized newly developed 3D structure models for all human STATs.
• Employed a pipeline combining comparative in silico docking of STAT-SH2 models.
• Integrated an in vitro STAT phosphorylation assay for screening compound libraries.

Main Results:

• The proposed pipeline enables screening of multi-million compound libraries.
• It facilitates the identification of specific inhibitors for different STATs.
• This approach addresses the need for more specific, potent, and bioavailable STAT inhibitors.

Conclusions:

• The developed pipeline offers a novel tool for discovering specific STAT inhibitors.
• Effective STAT inhibitors can advance our understanding of STAT roles in diseases.
• This approach holds promise for developing new therapeutic strategies for cancer, inflammation, and autoimmunity.